MiR-376b-3p Is Associated With Long-term Response to Sunitinib
in Metastatic Renal Cell Carcinoma Patients

J 2019

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, J. KOPECKY, O. FIALA et. al.

Basic information

Original name

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Authors

BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Jaroslav JURÁČEK (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), J. KOPECKY (203 Czech Republic), O. FIALA (203 Czech Republic), Marek SVOBODA (203 Czech Republic, belonging to the institution), Pavel FABIAN (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Petr BRABEC (203 Czech Republic, belonging to the institution), T. BUCHLER (203 Czech Republic) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2019, 1109-6535

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.280

RIV identification code

RIV/00216224:14740/19:00108589

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.21873/cgp.20140

UT WoS

000483944900005

Keywords in English

Renal cell carcinoma; sunitinib; microRNA; prediction

Abstract

V originále

Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

Links

NV15-34678A, research and development project

Name: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, J. KOPECKY, O. FIALA, Marek SVOBODA, Pavel FABIAN, Lenka RADOVÁ, Petr BRABEC, T. BUCHLER and Ondřej SLABÝ. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. CANCER GENOMICS & PROTEOMICS. ATHENS: INT INST ANTICANCER RESEARCH, 2019, vol. 16, No 5, p. 353-359. ISSN 1109-6535. Available from: https://dx.doi.org/10.21873/cgp.20140.

@article{1616997,
   author = {Bohošová, Júlia and Juráček, Jaroslav and Poprach, Alexandr and Kopecky, J. and Fiala, O. and Svoboda, Marek and Fabian, Pavel and Radová, Lenka and Brabec, Petr and Buchler, T. and Slabý, Ondřej},
   article_location = {ATHENS},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/cgp.20140},
   keywords = {Renal cell carcinoma; sunitinib; microRNA; prediction},
   language = {eng},
   issn = {1109-6535},
   journal = {CANCER GENOMICS & PROTEOMICS},
   title = {MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients},
   url = {http://cgp.iiarjournals.org/content/16/5/353.full},
   volume = {16},
   year = {2019}
}

TY  - JOUR
ID  - 1616997
AU  - Bohošová, Júlia - Juráček, Jaroslav - Poprach, Alexandr - Kopecky, J. - Fiala, O. - Svoboda, Marek - Fabian, Pavel - Radová, Lenka - Brabec, Petr - Buchler, T. - Slabý, Ondřej
PY  - 2019
TI  - MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
JF  - CANCER GENOMICS & PROTEOMICS
VL  - 16
IS  - 5
SP  - 353-359
EP  - 353-359
PB  - INT INST ANTICANCER RESEARCH
SN  - 11096535
KW  - Renal cell carcinoma
KW  - sunitinib
KW  - microRNA
KW  - prediction
UR  - http://cgp.iiarjournals.org/content/16/5/353.full
L2  - http://cgp.iiarjournals.org/content/16/5/353.full
N2  - Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
ER  -

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, J. KOPECKY, O. FIALA, Marek SVOBODA, Pavel FABIAN, Lenka RADOVÁ, Petr BRABEC, T. BUCHLER and Ondřej SLABÝ. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. \textit{CANCER GENOMICS \&{}amp; PROTEOMICS}. ATHENS: INT INST ANTICANCER RESEARCH, 2019, vol.~16, No~5, p.~353-359. ISSN~1109-6535. Available from: https://dx.doi.org/10.21873/cgp.20140.

Detailed Information on Publication Record